You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • AB0481 Demonstrated, quantifiable benefits in patient reported outcomes supporting a “treat to target” paradigm for infliximab-treated RA patients previously inadequately responsive to prior anti-TNF treatment

Article metrics

Article menu
Download PDFPDF
Scientific Abstracts
Abstracts accepted for publication
Rheumatoid arthritis – anti-TNF therapy
AB0481 Demonstrated, quantifiable benefits in patient reported outcomes supporting a “treat to target” paradigm for infliximab-treated RA patients previously inadequately responsive to prior anti-TNF treatment

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 2014300
Mar 2014900
Apr 2014400
May 2014300
Jun 2014200
Aug 2014500
Sep 2014400
Oct 2014400
Nov 2014500
Dec 2014300
Jan 20151302
Mar 2015700
Apr 2015300
May 2015101
Jun 2015100
Jul 2015500
Aug 2015100
Sep 2015510
Oct 2015300
Nov 2015602
Dec 2015200
Jan 2016200
Feb 2016400
Mar 2016200
May 2016100
Jun 2016300
Jul 2016200
Aug 2016200
Sep 2016300
Oct 2016200
Nov 2016200
Dec 2016200
Jan 2017400
Feb 2017700
Mar 2017600
Apr 2017200
May 2017200
Jun 2017500
Aug 20171000
Sep 2017800
Oct 20171600
Nov 2017400
Dec 2017800
Jan 20181000
Feb 2018200
Mar 20181200
Apr 20181001
May 20181001
Jun 2018800
Jul 20181000
Aug 2018600
Sep 2018200
Oct 2018400
Nov 2018400
Feb 2019800
Apr 2019200
Jul 2019200
Sep 2019200
Dec 2019200
Jan 2020300
Apr 2020200
Jun 2020400
Jul 2020600
Aug 2020100
Sep 20201001
Nov 2020100
Dec 2020400
Jan 2021400
Apr 2021400
Oct 2021400
Nov 20211001
Dec 2021600
Jan 2022400
Feb 2022300
Mar 2022400
Apr 2022600
May 2022600
Jun 2022200
Jul 20221600
Aug 2022400
Sep 2022700
Oct 2022400
Nov 20222100
Dec 2022700
Jan 2023400
Feb 20231000
Mar 2023400
Apr 2023600
May 2023200
Jul 2023200
Sep 2023400
Dec 2023600
Jan 2024200
Feb 2024400
Mar 2024200
Total46919